In a new study, an experimental obesity drug from Novo Nordisk, CagriSema allowed people to lose more than 20% of their body weight, on average, a result that caused the Danish company's stock price to fall by as much as 29%. Yes, fall. For anyone not following the heated race for obesity drug dominance, it may look like we're living upside-down. After all, if this data were unveiled three years ago, the market reaction would have been wildly different. The stock might have gone up and headlines would have heralded an advance in the fight against obesity. But we're in a new era of obesity medicine. The bar for success, once modest, has soared—especially so for CagriSema. Let me explain.
Though Novo will make mind-blowing money from its existing obesity drugs in the coming years (its GLP-1 drugs are likely to become pharma's most lucrative franchise next year), CagriSema was seen as essential for continued growth in 2030 and beyond. And the study suggests it may not be the contender investors had hoped for.
This story is from the January 02, 2025 edition of Mint Bangalore.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber ? Sign In
This story is from the January 02, 2025 edition of Mint Bangalore.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber? Sign In
Now, Tech Tools to Test Cortisol, Soothe Anxiety
A range of tech tools for mental health will be showcased at CES '25 in Vegas
This could be the best core exercise you've never done
A modification of the Zercher squat, the 'ab squat' is a dynamic workout that completely engages your core
For a balanced life, take the heroine's journey
Living a life not attuned to nature's cycles can affect the body and cause digestive issues as well as mental stress
AIF industry: At risk of death by a thousand circulars
Alternative investment funds generate value but have been dealt a harsh blow by over-regulation
Welfare programmes impact the retail prices relevant to people
India must update its inflation metrics to reflect actual consumption expenditure patterns for superior policy formulation
Expect Trump's crackdown on immigration to be disruptive
He is far better placed to act swiftly and harshly this time around
Rupee depreciation is inevitable but its volatility is not
RBI should restrain its active forex management while the Centre aims to attract more dollars
Tweaked for flexibility, NPS awaits tax clarity
This funded pension scheme now offers access to low-cost fund management with its option of staggered withdrawals of what was once a lump-sum. Good. Let's keep its taxation benign
Simplifying Taxes: Key Challenges for Budget 2025
As the budget season approaches, anticipation grows over how the government will balance growth ambitions and fiscal responsibility.
Ten big GenAI developments we saw within the span of a month
Its evolution didn't even pause for a year-end break as the AI wave began turning into a tsunami
